An interventional study of Modular powered orthosis in Lower-limb Orthoses, Frailty/Sarcopenia and Chronic Overuse Musculoskeletal Injuries, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Michigan · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 185 studies in Frailty with a site in United States — 48 open to participants now, 61 under way, 1 of them phase 3. Frailty · United States.
Among the 185 studies in Frailty with a site in United States, this one is the 101st largest by enrollment of the 142 interventional ones that give a count, is one of 19 that started in 2022, is one of 93 with no phase, and was the 112th registered.
1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.
Browse Frailty studies →48 of the 185 studies in Frailty with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 55+
University of California, San Francisco · Sites in United States
Ages 18–75
Longevity Metrics, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
William Brandenburg, MD · Sites in United States
Ages 18+ · Healthy volunteers
Longevity Metrics, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
185 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 32 · Phase 3 5 · Phase 4 5
First in 2001; this study’s year is marked. 19 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 83 across 772 interventional studies indexed under Frailty.
Median enrollment 42 across the 142 interventional studies, 128 across the 42 observational. Of the 113 that completed or were terminated, 43 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 185 have an industry lead sponsor. The 10 most frequent:
University of Michigan is the lead sponsor of 1,509 studies on the registry; 194 are open to participants now.
Of its 170 completed or terminated interventional studies of FDA-regulated products, 134 (79%) have results posted.
University of Michigan has 4 studies filed under Frailty — fewer than ten, so there is no comparison to draw.
24 of the studies in Frailty with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
| NCT03675724Mayo ClinicAlleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults | 2026-11 |
| NCT03430037Mayo ClinicAlleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women | 2026-11 |
| NCT07220512Wake Forest University Health SciencesThe Better, Harder, Faster, Stronger Study | 2026-11 |
| NCT06404970VA Office of Research and DevelopmentA Partnered Evaluation to Improve the Identification and Management of Functional Impairment and Frailty Among Older Veterans in Primary Care Settings | 2026-11-30 |
Add all 24 to your calendar (.ics) → With an account.
Among the 185 studies in Frailty with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall goal of this project is to develop modular, lower-limb, powered orthoses that fit to user-specific weakened joints and control force/torque in a manner that enhances voluntary motion in broad patient populations. This project aims to establish feasibility of assisting different populations with these modular powered orthoses. The investigators hypothesize that assisting lower-limb musculature with modular powered orthoses will improve 1) lifting/lowering posture in able-bodied subjects and 2) functional outcomes in elderly subjects.
The overall goal of this project is to develop modular, lower-limb, powered orthoses that fit to user-specific weakened joints and control force/torque in a manner that enhances voluntary motion in broad patient populations. Conventional orthoses tend to immobilize joints, and emerging powered orthoses constrain voluntary motion by using highly geared electric motors and/or control methods that force the user to follow a specific gait pattern. Consequently, these devices have not seen widespread success across populations with weakened voluntary control due to advanced age, musculoskeletal disorders, etc. These heterogeneous populations require partial, not full, assistance of user-specific muscle groups during daily activities. However, there is a fundamental gap in knowledge about how to design and control powered orthoses to assist the user without constraining their motion. The central hypothesis of this project is that high-torque, low-inertia motor systems controlled with energetic objectives will enable modular powered orthoses to partially assist the joints. High-torque electric motors combined with minimal transmissions can be freely rotated (i.e., backdriven) by human joints, allowing the use of an emerging torque control method called energy shaping to reduce the perceived weight/inertia of the body during any motion. By mounting these modular actuators to commercial orthoses, this technology will be easily prescribed/configured by clinicians. This project aims to establish feasibility of assisting different populations with modular powered orthoses. The investigators hypothesize that assisting lower-limb musculature with modular powered orthoses will improve 1) lifting/lowering posture in able-bodied subjects and 2) functional outcomes in elderly subjects.
Inclusion criteria for able-bodied, young participants will be:
Exclusion criteria for able-bodied, young adult participants will be:
Inclusion criteria for elderly participants will be:
Exclusion criteria for elderly participants will be:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm of the study will perform various tasks while wearing the modular powered orthosis
Device: Modular powered orthosis
This study will investigate modular, lower-limb, powered orthoses that fit to user-specific weakened joints and control force/torque in a manner that enhances voluntary motion in broad patient populations. The central hypothesis is that high-torque, low-inertia motor systems controlled with energetic objectives will enable modular powered orthoses to partially assist the joints. High-torque electric motors combined with minimal transmissions can be freely rotated (i.e., backdriven) by human joints, allowing the use of an emerging torque control method called energy shaping to reduce the perceived weight/inertia of the body during any motion. By mounting these modular actuators to commercial orthoses, this technology will be easily prescribed/configured by clinicians.
Muscle Effort (% MVC) With and Without Powered Orthosis - Able Bodied 1
For each orthosis module tested, electromyography (EMG) readings will be normalized per-muscle by the peak EMG observed during the no-orthosis condition, and then averaged over the cycle and across repetitions to obtain "normalized exertion" values. Data are presented as Muscle Effort (% Maximum Voluntary Contraction (MVC). Participants completed active movement trials and multi-terrain circuit loops under randomized conditions: 1) Baseline unassisted (No Exoskeleton) and 2) Assisted with active orthosis joint configurations running trajectory-free, task-invariant torque control via energy-shaping algorithms.
Time frame: 1 day
Quadriceps Muscle Effort (% MVC) With and Without Powered Orthosis - Able Bodied 2
We estimated quadriceps effort during six different lifting, lowering, and carrying (LLC) tasks (lifting-lowering (LL), level walking (LW), ramp ascent (RA), ramp descent (RD), stair ascent (SA), and stair descent (SD)) for the no-exo and exo conditions in a nonfatigued state. Muscle effort was calculated as the mean root mean square EMG, normalized to % maximum voluntary contraction (%MVC), over the gait/task cycle. Quadriceps effort was estimated by taking the weighted mean of the efforts of the vastus medialis oblique (VMO), vastus lateralis (VL), and rectus femoris (RF) based on their respective physiological cross-sectional areas.
Time frame: 1 day
Time to Complete 10 Reps of Lifting/Lowering
Time to complete 10 reps of L\&L will be measured post-fatigue in healthy subjects. The reported outcome is measured in seconds to completion.
Time frame: 1 day, assessed per experimental condition (i.e. with orthosis and without orthosis)
Gait Speed
Gait speed will be determined by the time to complete a 10-meter walk test. This will be the primary outcome measure for elderly subjects.
Time frame: 1 day, assessed per experimental condition (i.e. with orthosis and without orthosis)
Powered Orthosis Effect (Biological Torque)
For each orthosis module tested, peak biological torque (estimated by inverse dynamics) will be averaged across repetitions. Performance will be assessed by the difference between the orthosis condition and no-orthosis condition, averaging across tasks. Participants walked on a Bertec instrumented treadmill with a level slope at 1.0 and 1.2 m/s, a 5◦-inclined and 5◦-declined slope at 1.0 m/s, and a 10◦-inclined and 10◦-declined slope at 0.8 m/s. Participants also performed stair ascent and descent on a 5-step staircase with 7 in (178 mm) step height, and STS transitions from a knee-height chair. All activities were performed both with the powered exoskeleton and without. Results are presented as mean torque (Newton-meters per kilogram (Nm/kg).
Time frame: 1 day, assessed per experimental condition (i.e. with orthosis and without orthosis)
Minimum Chair Height for Successful Sit-to-stand
We will evaluate the minimum chair height from which elderly participants can successfully rise with and without the knee exoskeleton.
Time frame: 1 day, assessed per experimental condition (i.e. with orthosis and without orthosis)
Joint Power
For elderly participants, we will evaluate the peak values of biological and total (exo+biological) joint power at the hip with and without the exoskeleton. Results presented as mean power in watts per kilogram (W/kg).
Time frame: 1 day, assessed per experimental condition (i.e. with orthosis and without orthosis)
User Satisfaction
User satisfaction / perception of device effectiveness over an ambulation circuit (sit-to-stand, walk up and down a ramp, walk up and down a staircase) will be measured post-fatigue in healthy subjects using a modified Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) survey. The purpose of the scale is to evaluate user device satisfaction and consists of 12 items asking the user to rate their satisfaction on a scale of 1 to 5, where 1 = "not satisfied at all" and 5 = "very satisfied". The categories subjects were asked to rate were: Lifting/Lowering (LL), Ramp Ascent (RA), Stair Ascent (SA), Level walking (LW), Ramp Descent (RD), Stair Descent (SD)
Time frame: 1 day, assessed per experimental condition (i.e. with orthosis and without orthosis), with orthosis reported
Thorax Angle
This is the global thorax angle (with respect to vertical) during a lifting/lowering cycle. This will be a secondary outcome measure for able-bodied subjects. Extracted at peak trunk lean (bottom of the squat) across 10 post-fatigue cycles. Measured in degrees of decrease in global thorax angle compared with the no-exoskeleton condition.
Time frame: 1 day, assessed per experimental condition (i.e. with orthosis and without orthosis)
Stair Ascent Gait Style
Step-over-step gait style will be evaluated for the exo condition vs no exo condition for elderly participants.
Time frame: 1 day, assessed per experimental condition (i.e. with orthosis and without orthosis)
| Milestone | Able Bodied 1 w/o Device First, Then With Device | Able Bodied 1 Device First, Then w/o Device | Able Bodied 2 w/o Device First, Then With Device | Able Bodied 2 Device First, Then w/o Device | Elderly w/o Device First, Then With Device | Elderly Device First, Then w/o Device |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 6 | 4 | 5 | 4 |
| Completed | 4 | 4 | 6 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Able Bodied 1 w/o Device First, Then With Device | Able Bodied 1 Device First, Then w/o Device | Able Bodied 2 w/o Device First, Then With Device | Able Bodied 2 Device First, Then w/o Device | Elderly w/o Device First, Then With Device | Elderly Device First, Then w/o Device |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 6 | 4 | 4 | 4 |
| Completed | 4 | 4 | 6 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
For each orthosis module tested, electromyography (EMG) readings will be normalized per-muscle by the peak EMG observed during the no-orthosis condition, and then averaged over the cycle and across repetitions to obtain "normalized exertion" values. Data are presented as Muscle Effort (% Maximum Voluntary Contraction (MVC). Participants completed active movement trials and multi-terrain circuit loops under randomized conditions: 1) Baseline unassisted (No Exoskeleton) and 2) Assisted with active orthosis joint configurations running trajectory-free, task-invariant torque control via energy-shaping algorithms.
| Muscle Effort (% MVC) | Able Bodied 1: Without Orthosis | Able Bodied 1: With Orthosis |
|---|---|---|
| BARE - Vastus Medialis (VMO) - Stair Ascent | 33.887187841224 ± 7.6810749423049 | — |
| BARE - Rectus Femoris (RF) - Stair Ascent | 36.130551156563 ± 11.222455291190 | — |
| BARE - Biceps Femoris (BF) - Stair Ascent | 37.857660844087 ± 11.222472087944 | — |
| BARE - Gluteus Maximus (GLUT) - Stair Ascent | 35.308635582678 ± 11.530122508601 | — |
| BARE - Vastus Medialis (VMO) - Stair Descent | 26.89062659 ± 7.1137223474923 | — |
| BARE - Rectus Femoris (RF) - Stair Descent | 33.32355558 ± 8.6935226502226 | — |
| BARE - Biceps Femoris (BF) - Stair Descent | 18.008695800161 ± 6.3184176183671 | — |
| BARE - Gluteus Maximus (GLUT) - Stair Descent | 15.872367120956 ± 7.6361312369388 | — |
| BARE - Vastus Medialis (VMO) - Decline Walking | 26.01381243 ± 8.7596078012100 | — |
| BARE - Rectus Femoris (RF) - Decline Walking | 31.922145411886 ± 9.6338310891065 | — |
| BARE - Biceps Femoris (BF) - Decline Walking | 18.510995333101 ± 6.9317282676596 | — |
| BARE - Gluteus Maximus (GLUT) - Decline Walking | 15.256456799207 ± 6.1479183262170 | — |
| BARE - Vastus Medialis (VMO) - Level Walking | 8.90473025 ± 3.2483378245204 | — |
| BARE - Rectus Femoris (RF) - Level Walking | 9.8385978644759 ± 4.4030020038817 | — |
| BARE - Biceps Femoris (BF) - Level Walking | 15.369279160997 ± 5.2267456336351 | — |
| BARE - Gluteus Maximus (GLUT) - Level Walking | 14.896358394032 ± 5.9698236919873 | — |
| BARE - Vastus Medialis (VMO) - Incline Walking | 21.386952521881 ± 6.9835455215729 | — |
| BARE - Rectus Femoris (RF) - Incline Walking | 22.441831025994 ± 6.2533226937202 | — |
| BARE - Biceps Femoris (BF) - Incline Walking | 37.358377620674 ± 12.504330863689 | — |
| BARE - Gluteus Maximus (GLUT) - Incline Walking | 33.16334832 ± 9.7834405323076 | — |
| BARE - Vastus Medialis (VMO) - Stand Sit Cycle | 71.159426910594 ± 27.03307555 | — |
| BARE - Rectus Femoris (RF) - Stand Sit Cycle | 77.629740399435 ± 32.400533880317 | — |
| BARE - Biceps Femoris (BF) - Stand Sit Cycle | 52.006694506638 ± 23.590711319504 | — |
| BARE - Gluteus Maximus (GLUT) - Stand Sit Cycle | 47.288882465569 ± 20.425860285071 | — |
| HIP BILATERAL - Vastus Medialis (VMO) - Stair Ascent | — | 34.887019724155 ± 8.0329299363843 |
| HIP BILATERAL - Rectus Femoris (RF) - Stair Ascent | — | 34.175183898790 ± 10.558379040315 |
| HIP BILATERAL - Biceps Femoris (BF) - Stair Ascent | — | 39.31261713 ± 9.9135627911961 |
| HIP BILATERAL - Gluteus Maximus (GLUT) - Stair Ascent | — | 36.574630756003 ± 14.089783871097 |
| HIP BILATERAL - Vastus Medialis (VMO) - Stair Descent | — | 28.426617044617 ± 8.4696264634493 |
| HIP BILATERAL - Rectus Femoris (RF) - Stair Descent | — | 30.81723518 ± 10.795365660329 |
| HIP BILATERAL - Biceps Femoris (BF) - Stair Descent | — | 22.133788904854 ± 7.7152852205453 |
| HIP BILATERAL - Gluteus Maximus (GLUT) - Stair Descent | — | 16.361798804663 ± 6.4875895112257 |
| HIP BILATERAL - Vastus Medialis (VMO) - Decline Walking | — | 28.40680906 ± 9.7282329163926 |
| HIP BILATERAL - Rectus Femoris (RF) - Decline Walking | — | 32.004767039758 ± 10.404219512405 |
| HIP BILATERAL - Biceps Femoris (BF) - Decline Walking | — | 19.978603963324 ± 6.0899714941255 |
| HIP BILATERAL - Gluteus Maximus (GLUT) - Decline Walking | — | 14.462444972829 ± 5.5293432658697 |
| HIP BILATERAL - Vastus Medialis (VMO) - Level Walking | — | 11.063512759340 ± 5.0321315380417 |
| HIP BILATERAL - Rectus Femoris (RF) - Level Walking | — | 11.310608181945 ± 6.4665209346354 |
| HIP BILATERAL - Biceps Femoris (BF) - Level Walking | — | 16.792133858157 ± 5.1878589555683 |
| HIP BILATERAL - Gluteus Maximus (GLUT) - Level Walking | — | 15.540084316310 ± 4.8728352674184 |
| HIP BILATERAL - Vastus Medialis (VMO) - Incline Walking | — | 21.308361847529 ± 5.498142528 |
| HIP BILATERAL - Rectus Femoris (RF) - Incline Walking | — | 21.029887205033 ± 8.4578853663992 |
| HIP BILATERAL - Biceps Femoris (BF) - Incline Walking | — | 35.99796281 ± 11.692712930222 |
| HIP BILATERAL - Gluteus Maximus (GLUT) - Incline Walking | — | 33.538144326855 ± 12.131569564049 |
| HIP BILATERAL - Vastus Medialis (VMO) - Stand Sit Cycle | — | 77.35252186 ± 33.155698718153 |
| HIP BILATERAL - Rectus Femoris (RF) - Stand Sit Cycle | — | 78.75466021 ± 36.013813324420 |
| HIP BILATERAL - Biceps Femoris (BF) - Stand Sit Cycle | — | 53.406396350235 ± 22.056968489168 |
| HIP BILATERAL - Gluteus Maximus (GLUT) - Stand Sit Cycle | — | 45.23691184 ± 14.898291554987 |
| HIP UNILATERAL - Vastus Medialis (VMO) - Stair Ascent | — | 30.557272939686 ± 7.168393863 |
| HIP UNILATERAL - Rectus Femoris (RF) - Stair Ascent | — | 31.458243468999 ± 10.264130139094 |
| HIP UNILATERAL - Biceps Femoris (BF) - Stair Ascent | — | 36.314109673195 ± 7.6043325542087 |
| HIP UNILATERAL - Gluteus Maximus (GLUT) - Stair Ascent | — | 32.113290146370 ± 13.129542376906 |
| HIP UNILATERAL - Vastus Medialis (VMO) - Stair Descent | — | 23.309787621443 ± 5.3126186439685 |
| HIP UNILATERAL - Rectus Femoris (RF) - Stair Descent | — | 27.941707852616 ± 7.400397928 |
| HIP UNILATERAL - Biceps Femoris (BF) - Stair Descent | — | 18.731797638273 ± 5.0834466366617 |
| HIP UNILATERAL - Gluteus Maximus (GLUT) - Stair Descent | — | 15.362190727717 ± 8.3879846905768 |
| HIP UNILATERAL - Vastus Medialis (VMO) - Decline Walking | — | 24.919554151740 ± 7.5931918319512 |
| HIP UNILATERAL - Rectus Femoris (RF) - Decline Walking | — | 29.339789545456 ± 8.58673064 |
| HIP UNILATERAL - Biceps Femoris (BF) - Decline Walking | — | 18.033282507387 ± 5.7444802212869 |
| HIP UNILATERAL - Gluteus Maximus (GLUT) - Decline Walking | — | 13.923836823490 ± 6.7165758339868 |
| HIP UNILATERAL - Vastus Medialis (VMO) - Level Walking | — | 9.1280577788174 ± 4.5077511802951 |
| HIP UNILATERAL - Rectus Femoris (RF) - Level Walking | — | 9.9996041578801 ± 5.9642219584815 |
| HIP UNILATERAL - Biceps Femoris (BF) - Level Walking | — | 16.381193569910 ± 4.5633852069054 |
| HIP UNILATERAL - Gluteus Maximus (GLUT) - Level Walking | — | 14.096075840859 ± 6.0809695527673 |
| HIP UNILATERAL - Vastus Medialis (VMO) - Incline Walking | — | 17.916819010500 ± 5.6328724436092 |
| HIP UNILATERAL - Rectus Femoris (RF) - Incline Walking | — | 20.005200939484 ± 7.6253994162103 |
| HIP UNILATERAL - Biceps Femoris (BF) - Incline Walking | — | 29.744091347796 ± 9.1941385127750 |
| HIP UNILATERAL - Gluteus Maximus (GLUT) - Incline Walking | — | 29.675785709713 ± 12.415783262961 |
| HIP UNILATERAL - Vastus Medialis (VMO) - Stand Sit Cycle | — | 63.992088491865 ± 23.739619487200 |
| HIP UNILATERAL - Rectus Femoris (RF) - Stand Sit Cycle | — | 76.171714622490 ± 36.955527336261 |
| HIP UNILATERAL - Biceps Femoris (BF) - Stand Sit Cycle | — | 44.466855746443 ± 15.831705268999 |
| HIP UNILATERAL - Gluteus Maximus (GLUT) - Stand Sit Cycle | — | 41.561584347357 ± 41.561584347357 |
| KNEE BILATERAL - Vastus Medialis (VMO) - Stair Ascent | — | 33.547023647236 ± 15.699306295726 |
| KNEE BILATERAL - Rectus Femoris (RF) - Stair Ascent | — | 37.631989795988 ± 15.018897719695 |
| KNEE BILATERAL - Biceps Femoris (BF) - Stair Ascent | — | 45.105442873007 ± 14.181012143412 |
| KNEE BILATERAL - Gluteus Maximus (GLUT) - Stair Ascent | — | 56.93970866 ± 16.089185358511 |
| KNEE BILATERAL - Vastus Medialis (VMO) - Stair Descent | — | 28.734279007380 ± 12.803180669976 |
| KNEE BILATERAL - Rectus Femoris (RF) - Stair Descent | — | 37.256820163673 ± 15.647647925985 |
| KNEE BILATERAL - Biceps Femoris (BF) - Stair Descent | — | 26.090669575164 ± 7.8275101191662 |
| KNEE BILATERAL - Gluteus Maximus (GLUT) - Stair Descent | — | 26.060951621644 ± 14.542103085287 |
| KNEE BILATERAL - Vastus Medialis (VMO) - Decline Walking | — | 25.929086313111 ± 12.070117938470 |
| KNEE BILATERAL - Rectus Femoris (RF) - Decline Walking | — | 31.962328475160 ± 11.271358486429 |
| KNEE BILATERAL - Biceps Femoris (BF) - Decline Walking | — | 20.022683393847 ± 6.8826399251759 |
| KNEE BILATERAL - Gluteus Maximus (GLUT) - Decline Walking | — | 19.555111691492 ± 8.5773032128057 |
| KNEE BILATERAL - Vastus Medialis (VMO) - Level Walking | — | 14.558686062768 ± 4.3141426848920 |
| KNEE BILATERAL - Rectus Femoris (RF) - Level Walking | — | 14.177587403852 ± 7.6700608091222 |
| KNEE BILATERAL - Biceps Femoris (BF) - Level Walking | — | 18.788292114371 ± 9.1275626246146 |
| KNEE BILATERAL - Gluteus Maximus (GLUT) - Level Walking | — | 21.431169000247 ± 8.5209599057584 |
| KNEE BILATERAL - Vastus Medialis (VMO) - Incline Walking | — | 20.216411619688 ± 10.936416746878 |
| KNEE BILATERAL - Rectus Femoris (RF) - Incline Walking | — | 21.977697136970 ± 10.331109022759 |
| KNEE BILATERAL - Biceps Femoris (BF) - Incline Walking | — | 39.277194237640 ± 18.472651029130 |
| KNEE BILATERAL - Gluteus Maximus (GLUT) - Incline Walking | — | 45.622775924455 ± 14.543403783129 |
| KNEE BILATERAL - Vastus Medialis (VMO) - Stand Sit Cycle | — | 59.34141979 ± 42.900567533085 |
| KNEE BILATERAL - Rectus Femoris (RF) - Stand Sit Cycle | — | 61.597386942684 ± 46.65885237 |
| KNEE BILATERAL - Biceps Femoris (BF) - Stand Sit Cycle | — | 49.648592568233 ± 25.531725102560 |
| KNEE BILATERAL - Gluteus Maximus (GLUT) - Stand Sit Cycle | — | 46.969562202638 ± 22.790823800647 |
| KNEE UNILATERAL - Vastus Medialis (VMO) - Stair Ascent | — | 27.511615425730 ± 11.968935486044 |
| KNEE UNILATERAL - Rectus Femoris (RF) - Stair Ascent | — | 29.796357536863 ± 9.3224063189778 |
| KNEE UNILATERAL - Biceps Femoris (BF) - Stair Ascent | — | 37.327276657096 ± 10.471705525761 |
| KNEE UNILATERAL - Gluteus Maximus (GLUT) - Stair Ascent | — | 38.457339295197 ± 14.305192866717 |
| KNEE UNILATERAL - Vastus Medialis (VMO) - Stair Descent | — | 22.583211397798 ± 8.2649467504421 |
| KNEE UNILATERAL - Rectus Femoris (RF) - Stair Descent | — | 26.723273051711 ± 6.9100402095087 |
| KNEE UNILATERAL - Biceps Femoris (BF) - Stair Descent | — | 17.830434769382 ± 6.5263764018533 |
| KNEE UNILATERAL - Gluteus Maximus (GLUT) - Stair Descent | — | 18.394505135561 ± 8.5775126690267 |
| KNEE UNILATERAL - Vastus Medialis (VMO) - Decline Walking | — | 22.168556450131 ± 10.30921476 |
| KNEE UNILATERAL - Rectus Femoris (RF) - Decline Walking | — | 26.658100157732 ± 7.4886630168186 |
| KNEE UNILATERAL - Biceps Femoris (BF) - Decline Walking | — | 17.403907608170 ± 6.6949523140704 |
| KNEE UNILATERAL - Gluteus Maximus (GLUT) - Decline Walking | — | 16.685700226561 ± 6.488186651 |
| KNEE UNILATERAL - Vastus Medialis (VMO) - Level Walking | — | 10.980611289672 ± 4.2962490697954 |
| KNEE UNILATERAL - Rectus Femoris (RF) - Level Walking | — | 10.971384069935 ± 4.5761785130242 |
| KNEE UNILATERAL - Biceps Femoris (BF) - Level Walking | — | 13.52207812 ± 4.262612408 |
| KNEE UNILATERAL - Gluteus Maximus (GLUT) - Level Walking | — | 19.682798857130 ± 7.7534082351244 |
| KNEE UNILATERAL - Vastus Medialis (VMO) - Incline Walking | — | 16.815658523150 ± 5.5663406440699 |
| KNEE UNILATERAL - Rectus Femoris (RF) - Incline Walking | — | 17.462644623327 ± 5.4672997047989 |
| KNEE UNILATERAL - Biceps Femoris (BF) - Incline Walking | — | 31.382472868084 ± 11.726410757309 |
| KNEE UNILATERAL - Gluteus Maximus (GLUT) - Incline Walking | — | 36.252775416641 ± 9.2533322102647 |
| KNEE UNILATERAL - Vastus Medialis (VMO) - Stand Sit Cycle | — | 50.494278375684 ± 28.724065499894 |
| KNEE UNILATERAL - Rectus Femoris (RF) - Stand Sit Cycle | — | 58.769489599426 ± 29.519784441933 |
| KNEE UNILATERAL - Biceps Femoris (BF) - Stand Sit Cycle | — | 41.356263036694 ± 20.139622801561 |
| KNEE UNILATERAL - Gluteus Maximus (GLUT) - Stand Sit Cycle | — | 46.90339263 ± 20.481864636128 |
We estimated quadriceps effort during six different lifting, lowering, and carrying (LLC) tasks (lifting-lowering (LL), level walking (LW), ramp ascent (RA), ramp descent (RD), stair ascent (SA), and stair descent (SD)) for the no-exo and exo conditions in a nonfatigued state. Muscle effort was calculated as the mean root mean square EMG, normalized to % maximum voluntary contraction (%MVC), over the gait/task cycle. Quadriceps effort was estimated by taking the weighted mean of the efforts of the vastus medialis oblique (VMO), vastus lateralis (VL), and rectus femoris (RF) based on their respective physiological cross-sectional areas.
| % MVC | Able Bodied 2: Without Orthosis | Able Bodied 2: With Orthosis |
|---|---|---|
| Lifting-lowering (LL) | 25.39392547 ± 7.0486881 | 19.74086721 ± 5.281409738 |
| Ramp Ascent (RA) | 13.36036878 ± 6.516432213 | 11.09373192 ± 5.456759946 |
| Stair Ascent (SA) | 18.18997983 ± 9.166957862 | 13.62986533 ± 5.790605194 |
| Ramp Descent (RD) | 15.9386677 ± 6.733850985 | 14.60594334 ± 6.884032713 |
| Stair Descent (SD) | 16.47382229 ± 8.218553276 | 14.56048643 ± 6.438120934 |
| Level Walking (LW) | 7.836225154 ± 3.596847975 | 7.56271423 ± 3.56607281 |
Time to complete 10 reps of L\&L will be measured post-fatigue in healthy subjects. The reported outcome is measured in seconds to completion.
| time in seconds | Able Bodied 2: Without Orthosis | Able Bodied 2: With Orthosis |
|---|---|---|
| Time to Complete 10 Reps of Lifting/Lowering | 52.11 ± 15.79223946 | 36.15666667 ± 4.986625322 |
Gait speed will be determined by the time to complete a 10-meter walk test. This will be the primary outcome measure for elderly subjects.
No measurements were reported for this outcome.
For each orthosis module tested, peak biological torque (estimated by inverse dynamics) will be averaged across repetitions. Performance will be assessed by the difference between the orthosis condition and no-orthosis condition, averaging across tasks. Participants walked on a Bertec instrumented treadmill with a level slope at 1.0 and 1.2 m/s, a 5◦-inclined and 5◦-declined slope at 1.0 m/s, and a 10◦-inclined and 10◦-declined slope at 0.8 m/s. Participants also performed stair ascent and descent on a 5-step staircase with 7 in (178 mm) step height, and STS transitions from a knee-height chair. All activities were performed both with the powered exoskeleton and without. Results are presented as mean torque (Newton-meters per kilogram (Nm/kg).
| Torque (Nm/kg) | Exoskeleton - Elderly: Without Orthosis | Exoskeleton - Elderly: With Orthosis |
|---|---|---|
| Level Ground 1.0 m/s | 0.4754 ± 0.1126 | 0.4041 ± 0.1035 |
| Level Ground 1.2 m/s | 0.5796 ± 0.1473 | 0.5042 ± 0.0895 |
| Ramp Ascent 5 degrees | 0.5373 ± 0.1083 | 0.4777 ± 0.1286 |
| Ramp Ascent 10 degrees | 0.5896 ± 0.0898 | 0.4585 ± 0.1344 |
| Stair Ascent | 1.2046 ± 0.2866 | 0.9801 ± 0.399 |
| Sit-to-Stand | 0.78 ± 0.2106 | 0.6341 ± 0.1779 |
We will evaluate the minimum chair height from which elderly participants can successfully rise with and without the knee exoskeleton.
| inches | Exoskeleton - Elderly: Without Orthosis | Exoskeleton - Elderly: With Orthosis |
|---|---|---|
| Minimum Chair Height for Successful Sit-to-stand | 16.00 ± 2.31 | 14.25 ± 2.63 |
For elderly participants, we will evaluate the peak values of biological and total (exo+biological) joint power at the hip with and without the exoskeleton. Results presented as mean power in watts per kilogram (W/kg).
| Power (W/kg) | Exoskeleton - Elderly: Without Orthosis | Exoskeleton - Elderly: With Orthosis |
|---|---|---|
| Level Ground1.0 m/s (biological) | 0.7356 ± 0.1783 | 0.706 ± 0.2983 |
| Level Ground 1.0 m/s (exo + bio) | 0.7356 ± 0.1783 | 0.9855 ± 0.3533 |
| Level Ground 1.2 m/s (biological) | 0.9335 ± 0.235 | 0.9788 ± 0.3406 |
| Level Ground 1.2 m/s (exo + bio) | 0.9335 ± 0.235 | 1.2676 ± 0.3815 |
| Ramp Ascent 5 (degrees) (biological) | 0.9682 ± 0.198 | 0.8093 ± 0.2753 |
| Ramp Ascent 5 (degrees) (exo + bio)) | 0.9682 ± 0.198 | 1.1145 ± 0.3172 |
| Ramp Ascent 10 (degrees) (biological) | 0.9798 ± 0.2095 | 0.7932 ± 0.2557 |
| Ramp Ascent 10 (degrees) (exo + bio) | 0.9798 ± 0.2095 | 1.1249 ± 0.2779 |
| Stair Ascent (biological) | 2.3544 ± 0.7276 | 1.9235 ± 0.7198 |
| Stair Ascent (exo + bio) | 2.3544 ± 0.7276 | 2.4858 ± 0.7458 |
| Sit-to-Stand (biological) | 1.478 ± 1.0299 | 1.1623 ± 0.9483 |
| Sit-to-Stand (exo + bio) | 1.478 ± 1.0299 | 1.6599 ± 1.3195 |
User satisfaction / perception of device effectiveness over an ambulation circuit (sit-to-stand, walk up and down a ramp, walk up and down a staircase) will be measured post-fatigue in healthy subjects using a modified Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) survey. The purpose of the scale is to evaluate user device satisfaction and consists of 12 items asking the user to rate their satisfaction on a scale of 1 to 5, where 1 = "not satisfied at all" and 5 = "very satisfied". The categories subjects were asked to rate were: Lifting/Lowering (LL), Ramp Ascent (RA), Stair Ascent (SA), Level walking (LW), Ramp Descent (RD), Stair Descent (SD)
| score on a scale | Exoskeleton - Able Bodied 2: Without Orthosis | Exoskeleton - Able Bodied 2: With Orthosis |
|---|---|---|
| Lifting/Lowering (LL) | — | 4.8 ± 0.421637021 |
| Ramp Ascent (RA) | — | 4.2 ± 0.421637021 |
| Stair Ascent (SA) | — | 4.8 ± 0.421637021 |
| Level walking (LW) | — | 3.6 ± 0.699205899 |
| Ramp Descent (RD) | — | 4.2 ± 0.788810638 |
| Stair Descent (SD) | — | 4.3 ± 1.059349905 |
This is the global thorax angle (with respect to vertical) during a lifting/lowering cycle. This will be a secondary outcome measure for able-bodied subjects. Extracted at peak trunk lean (bottom of the squat) across 10 post-fatigue cycles. Measured in degrees of decrease in global thorax angle compared with the no-exoskeleton condition.
| Degrees | Exoskeleton - Able Bodied 2: Without Orthosis | Exoskeleton - Able Bodied 2: With Orthosis |
|---|---|---|
| Thorax Angle | 53.271 ± 9.072 | 48.918 ± 9.448 |
Step-over-step gait style will be evaluated for the exo condition vs no exo condition for elderly participants.
| Participants | Exoskeleton - Elderly: Without Orthosis | Exoskeleton - Elderly: With Orthosis |
|---|---|---|
| Stair Ascent Gait Style | 7 | 8 |
Collected over 2 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Able Bodied 1 Without Device | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Able Bodied 1 With Device | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Able Bodied 2 Without Device | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Able Bodied 2 With Device | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Elderly Without Device | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Elderly With Device | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Event | Able Bodied 1 Without Device | Able Bodied 1 With Device | Able Bodied 2 Without Device | Able Bodied 2 With Device | Elderly Without Device | Elderly With Device |
|---|---|---|---|---|---|---|
| Non-Serious Adverse EventInjury, poisoning and procedural complications | 0/4 | 0/4 | 0/6 | 0/4 | 1/4 | 0/4 |
Age, sex, race/ethnicity, and weight were collected for all baseline participants. Height was not collected or reported for group 1. For group 3 (Exoskeleton - elderly), 9 participants were consented and enrolled but only 8 had baseline characteristics collected and finished the study.
| Age, Categorical(Participants) | Exoskeleton - Able Bodied 1 | Exoskeleton - Able Bodied 2 | Exoskeleton - Elderly | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 10 | 0 | 18 |
| >=65 years | 0 | 0 | 9 | 9 |
| Sex: Female, Male(Participants) | Exoskeleton - Able Bodied 1 | Exoskeleton - Able Bodied 2 | Exoskeleton - Elderly | Total |
|---|---|---|---|---|
| Female | 4 | 5 | 4 | 13 |
| Male | 4 | 5 | 5 | 14 |
| Race/Ethnicity, Customized(Participants) | Exoskeleton - Able Bodied 1 | Exoskeleton - Able Bodied 2 | Exoskeleton - Elderly | Total |
|---|---|---|---|---|
| Race/Ethnicity — White Non-Hispanic | 4 | 6 | 9 | 19 |
| Race/Ethnicity — Black or African American | 0 | 0 | 0 | 0 |
| Race/Ethnicity — Asian | 3 | 3 | 0 | 6 |
| Race/Ethnicity — Hispanic or Latino | 1 | 1 | 0 | 2 |
| Weight(Mass (kg)) | Exoskeleton - Able Bodied 1 | Exoskeleton - Able Bodied 2 | Exoskeleton - Elderly | Total |
|---|---|---|---|---|
| Mean | 69.25 ± 12.17 | 69.9 ± 13.24 | 69.11 ± 7.03 | 69.46 ± 10.89 |
| Height(Height (meters)) | Exoskeleton - Able Bodied 1 | Exoskeleton - Able Bodied 2 | Exoskeleton - Elderly | Total |
|---|---|---|---|---|
| Mean | — | 1.70 ± 0.07 | 1.72 ± 0.04 | 1.71 ± 0.06 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jul 2022 to primary completion in Aug 2025, 36 months.
Results were first posted in Nov 2026, 1 year 3 months after primary completion.
Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's 36 months is above that.
Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Sep 2026 → Aug 2025 and completion Sep 2026 → Aug 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.